Zilberberg Marya D, Kollef Marin H, Shorr Andrew F
EviMed Research Group, LLC, Goshen, Massachusetts.
School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts.
J Hosp Med. 2016 Jan;11(1):21-6. doi: 10.1002/jhm.2477. Epub 2015 Sep 9.
Acinetobacter baumannii (AB) has evolved a variety of resistance mechanisms and exhibits unpredictable susceptibility patterns, making it difficult to select empiric therapy.
To examine US secular trends in the resistance of AB in respiratory infections and blood stream infections (BSI) to antimicrobial agents whose effectiveness is supported in the literature
Survey.
We analyzed 3 time periods (2003-2005, 2006-2008, 2009-2012) in Eurofins' The Surveillance Network for resistance of AB to the following antimicrobials: carbapenems (imipenem, meropenem, doripenem), aminoglycosides (tobramycin, amikacin), tetracyclines (minocycline, doxycycline), polymyxins (colistin, polymyxin B), ampicillin-sulbactam, and trimethoprim-sulfamethoxazole. Resistance to ≥3 drug classes defined multidrug resistance (MDR).
We identified 39,320 AB specimens (81.1% respiratory, 18.9% BSI). The highest prevalence of resistance was to doripenem (90.3%) followed by trimethoprim-sulfamethoxazole (55.3%), and the lowest to colistin (5.3%). Resistance to carbapenems (21.0% in 2003-2005 and 47.9% in 2009-2012) and colistin (2.8% in 2006-2008 to 6.9% in 2009-2012) more than doubled. Prevalence of MDR AB rose from 21.4% in 2003 to 2005 to 33.7% in 2006 to 2008, and remained stable at 35.2% in 2009 to 2012. In contrast, resistance to minocycline diminished from 56.5% (2003-2005) to 30.5% (2009-2012). MDR organisms were most frequent in nursing homes (46.5%), followed by general ward (29.2%), intensive care unit (28.7%), and outpatient setting (26.2%).
Resistance rates among AB to such last-resort antimicrobials as carbapenems and colistin are on the rise, whereas that to minocycline has declined. Nursing homes are a reservoir of resistant AB. These trends should inform not only empiric treatment of serious infections, but also approaches to infection control.
鲍曼不动杆菌(AB)已进化出多种耐药机制,且药敏模式难以预测,这使得经验性治疗的选择变得困难。
研究美国呼吸道感染和血流感染(BSI)中AB对文献中支持有效的抗菌药物的耐药性长期趋势。
调查。
我们分析了欧陆科仪监测网络中3个时间段(2003 - 2005年、2006 - 2008年、2009 - 2012年)AB对以下抗菌药物的耐药情况:碳青霉烯类(亚胺培南、美罗培南、多利培南)、氨基糖苷类(妥布霉素、阿米卡星)、四环素类(米诺环素、多西环素)、多粘菌素类(黏菌素、多粘菌素B)、氨苄西林 - 舒巴坦以及甲氧苄啶 - 磺胺甲恶唑。对≥3类药物耐药定义为多重耐药(MDR)。
我们共鉴定出39320份AB标本(81.1%为呼吸道标本,18.9%为BSI标本)。耐药率最高的是多利培南(90.3%),其次是甲氧苄啶 - 磺胺甲恶唑(55.3%),最低的是黏菌素(5.3%)。对碳青霉烯类的耐药率(2003 - 2005年为21.0%,2009 - 2012年为47.9%)和黏菌素的耐药率(2006 - 2008年为2.8%,2009 - 2012年为6.9%)增加了一倍多。MDR AB的患病率从2003 - 2005年的21.4%上升至2006 - 2008年的33.7%,并在2009 - 2012年稳定在35.2%。相比之下,对米诺环素的耐药率从56.5%(2003 - 2005年)降至30.5%(2009 - 2012年)。MDR菌在疗养院最为常见(46.5%),其次是普通病房(29.2%)、重症监护病房(28.7%)和门诊(26.2%)。
AB对碳青霉烯类和黏菌素等最后手段抗菌药物的耐药率在上升,而对米诺环素的耐药率有所下降。疗养院是耐药AB的储存库。这些趋势不仅应为严重感染的经验性治疗提供依据,也应为感染控制方法提供参考。